Allogene Therapeutics Stock News

Morgan Stanley boosted its holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 1,107.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,129,478 shares of the companys stock after purchasing an additional 1,035,898 shares during the period. Morgan Stanley owned about 0.79% of []

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

Allogene (ALLO) misses earnings estimates for the third quarter. However, the stock rises in after-market trading.

Allogene Therapeutics' (ALLO) CEO David Chang on Q3 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCA

NEW YORK, Oct. 15, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO).  Such investors a

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Allogene Therapeutics: I Am Buying On The Clinical Hold Dip

Investors need to pay close attention to Allogene (ALLO) stock based on the movements in the options market lately.

New York, New York--(Newsfile Corp. - October 8, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Allogene Therapeutics, Inc. ("Allogene" or the "Company") (NASDAQ: ALLO). Such

Shares of Allogene Therapeutics Inc (NASDAQ: ALLO) tanked 45% to $13.35 on Friday after the U.S. FDA put a hold on its Cancer drug trial. The sharp decline wiped millions off Allogene's market cap, le

A possible safety issue is crushing the biotech's shares today.

The FDA places Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates on hold, following chromosomal abnormality observed in an early-stage study patient receiving ALLO-501A.

Allogene Therapeutics Inc (NASDAQ:ALLO) is plummeting this morning, down 42% to trade at $14.13 at last check, one of the worst stock's on the Nasdaq today.

The FDA has sent shockwaves through the off-the-shelf CAR-T space after it slapped a clinical hold on all of the Allogene Therapeutics Inc (NASDAQ: ALLO) AlloCAR T trials in response to an abnorma